Aspirin Per Se (i.e., 2-(acetyloxy)benozic Acid) Patents (Class 514/165)
-
Patent number: 10874653Abstract: The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.Type: GrantFiled: August 27, 2018Date of Patent: December 29, 2020Assignee: Sen-Jam Pharmaceutical LLCInventors: Jacqueline M. Iversen, Thomas A. Dahl
-
Patent number: 10857106Abstract: Methods for treating and/or delaying onset of dysplastic lesions in the bronchial airway of an individual comprise delivering to the respiratory track of the individual an inhalable dry powder composition including an effective amount of myo-inositol.Type: GrantFiled: February 12, 2018Date of Patent: December 8, 2020Assignees: The Regents of the University of Colorado, a Body Corporate, Aktiv-Dry LLCInventors: Robert E. Sievers, Stephen Cape, David McAdams, J'aime Manion, Pankaj Pathak
-
Patent number: 10828286Abstract: In some embodiments, the present disclosure pertains to a composition including niacin up to about 1000 mg and berberine up to about 800 mg. In some embodiments, the niacin is in an amount of about 500 mg and the berberine is in an amount of about 100 mg. In some embodiments, the present disclosure pertains to a method that includes administering a composition to a subject in need thereof, where the composition includes niacin up to about 1000 mg and berberine up to about 800 mg. In some embodiments, the niacin is in an amount of about 500 mg and the berberine is in an amount of about 100 mg.Type: GrantFiled: May 22, 2019Date of Patent: November 10, 2020Assignee: GM Pharmaceuticals, Inc.Inventor: Odes W. Mitchell
-
Patent number: 10695309Abstract: Disclosed herein are sustained release Liothyronine oral capsule formulations, methods of making the formulations and use to treat hypothyroidism, a thyroid deficient disease state, or thyroid dysfunction.Type: GrantFiled: March 30, 2018Date of Patent: June 30, 2020Assignee: WESTERN NEW ENGLAND UNIVERSITYInventors: Shabnam N. Sani, Hamid Bakhteyar
-
Patent number: 10568858Abstract: The present invention encompasses oils that have anti-inflammatory or resolution-stimulating activity that contain or are enriched with Specialized Proresolving Mediators (SPM) or SPM precursors, which originate from an oil obtained from organisms containing long chain omega-3 polyunsaturated fatty acids, such as fish, crustaceae, algae, and mollusks. The invention also encompasses a method for the production of these oils, and the utilization of the oils for nutritional supplements, pharmaceutical formulations, and cosmetic formulations, which can be employed for treating an inflammatory condition.Type: GrantFiled: May 9, 2013Date of Patent: February 25, 2020Assignee: SOLUTEX NA LLCInventors: Gerhardus Lucas Bannenberg, Charles Nicholas Serhan, Fernando Moreno Egea
-
Patent number: 10456469Abstract: The present invention is a glutamine compound having a non-radioisotope high Z element attached via a linker, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.Type: GrantFiled: March 3, 2017Date of Patent: October 29, 2019Assignee: SERBIG PHARMACEUTICALS CORP.Inventor: Pedro Anastacio Serrano-Ojeda
-
Patent number: 10391080Abstract: Methods of treating cancer, including PAR-4 implicated cancers or renal cell carcinoma, using ketorolac are disclosed herein. Ketorolac can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.Type: GrantFiled: July 10, 2017Date of Patent: August 27, 2019Assignee: Cipla LimitedInventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
-
Patent number: 10391096Abstract: A method for treating thrombotic disorders using a composition containing quercetin, together with one or more of vitamin B3, vitamin C, and folic acid. Also disclosed is a method of improving the efficacy of a blood thinning medication by co-administering a composition containing quercetin, together with one or more of vitamin B3, vitamin C, and folic acid to a subject being treated with a blood thinning medication.Type: GrantFiled: October 13, 2011Date of Patent: August 27, 2019Assignee: Quercegen Pharmaceuticals LLCInventor: Thomas Christian Lines
-
Patent number: 10238622Abstract: The invention provides methods of treatment that prevent the onset of Mesial temporal lobe epilepsy (TLE) in a subject, or which reduce the severity of TLE in a subject, by administering a NKCC1 inhibitor to the subject after the subject has suffered from an insult known to precipitate TLE.Type: GrantFiled: July 23, 2010Date of Patent: March 26, 2019Inventors: Wolfgang S. Mueller, John A. Connor, Steven Peterson, Denis Bragin
-
Patent number: 10124005Abstract: Migraine is a multi-symptom disease involving pain; histamine triggers; and nausea with or without vomiting. Current over-the-counter medications focus only on treating pain. This invention involves treating other common triggers and symptoms as well as pain. Acetaminophen and caffeine are already being used but the addition of meclizine is what makes this medication my invention. The addition of meclizine covers the other symptoms that make migraine sufferers miserable which is nausea/vomiting and treats the possible histamine mediated trigger of migraines because it has antihistaminic properties. As a migraine sufferer myself, I experience all of these symptoms and would very much like to have everything I need to cover these debilitating symptoms in one medication hence my invention.Type: GrantFiled: December 15, 2017Date of Patent: November 13, 2018Inventor: Lisa Josette Myslinski
-
Patent number: 10103225Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.Type: GrantFiled: April 12, 2018Date of Patent: October 16, 2018Inventors: Michelle Reillo, Marian E. Washington
-
Patent number: 10084044Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.Type: GrantFiled: April 12, 2018Date of Patent: September 25, 2018Inventors: Michelle Reillo, Marian E. Washington
-
Patent number: 10000735Abstract: The present invention relates to a medium composition containing an Ecklonia cava extract for dedifferentiating an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced pluripotent stem cell, produced by using the medium composition into a neuron. When using the medium composition according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into neurons.Type: GrantFiled: November 5, 2013Date of Patent: June 19, 2018Assignee: BBHC CO., LTD.Inventors: Sang Yeon Lee, Won Ju Jung, Ho Bin Kim, Min Sun Oh, Kye Ho Lee
-
Patent number: 9974763Abstract: A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.Type: GrantFiled: May 28, 2014Date of Patent: May 22, 2018Assignees: B&A THERAPEUTICS, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AUX MARSEILLE, UNIVERSITE DE NANTESInventors: Yehezkel Ben-Ari, Nathalie Dehorter, Philippe Damier, Constance Hammond
-
Patent number: 9956187Abstract: The invention relates to dezocine compositions and uses thereof. Specifically, the invention relates to dezocine compositions, including nano-dezocine compositions and methods for preventing or treating opioid receptor associated diseases, including neuropathic pain; addiction, such as opioid or cocaine addiction; and depression.Type: GrantFiled: April 9, 2015Date of Patent: May 1, 2018Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Renyu Liu, Geoffrey Krug, Feixiang Wu, Julie Blendy
-
Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine
Patent number: 9896411Abstract: Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.Type: GrantFiled: November 17, 2016Date of Patent: February 20, 2018Assignee: THEAPRIN PHARMACEUTICALS INC.Inventors: Harry G. Brittain, Philip V. Felice -
Patent number: 9839612Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.Type: GrantFiled: August 1, 2016Date of Patent: December 12, 2017Inventors: Michelle Reillo, Marian E. Washington
-
Patent number: 9750725Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Ra?, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.Type: GrantFiled: May 20, 2015Date of Patent: September 5, 2017Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Patent number: 9676715Abstract: Novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.Type: GrantFiled: July 20, 2012Date of Patent: June 13, 2017Assignee: UNIVERSITE JOSEPH FOURIERInventors: Jean-Noël Denis, Marcelle Claude Jolivalt, Louis Maurin Max Maurin, Matthieu Jeanty
-
Patent number: 9351980Abstract: The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives.Type: GrantFiled: February 15, 2011Date of Patent: May 31, 2016Assignee: The University of WolverhamptonInventors: Christopher John Perry, Iain Douglas Nicholl
-
Patent number: 9345678Abstract: Embodiments described herein are directed to prostanoid (IP) receptor agonist compounds, including cicaprost and certain prodrugs, and methods of preparation and use for the same. Certain embodiments are directed to the use of cicaprost and certain prodrugs in the treatment of topical and ocular conditions.Type: GrantFiled: March 11, 2014Date of Patent: May 24, 2016Assignee: ALLERGAN, INC.Inventors: Jenny W. Wang, David F. Woodward, Neil J. Poloso, Julia Herrmann
-
Patent number: 9321785Abstract: The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.Type: GrantFiled: August 7, 2013Date of Patent: April 26, 2016Assignee: IPCA Laboratories LimitedInventors: Ashok Kumar, Nellithanath Thankachen Byju
-
Patent number: 9308211Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.Type: GrantFiled: May 24, 2014Date of Patent: April 12, 2016Assignee: Infirst Healthcare LimitedInventors: John Brew, Robin Mark Bannister
-
Patent number: 9289440Abstract: A method of treating myocardial infarction in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.Type: GrantFiled: June 4, 2014Date of Patent: March 22, 2016Assignee: THEAPRIN PHARMACEUTICALS INC.Inventors: Harry G. Brittain, Philip V. Felice
-
Patent number: 9289439Abstract: A method of reducing hepatocellular damage in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.Type: GrantFiled: February 25, 2014Date of Patent: March 22, 2016Assignee: THEAPRIN PHARMACEUTICALS INC.Inventors: Harry G. Brittain, Philip V. Felice
-
Patent number: 9289438Abstract: A method of treating high grade temperature using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.Type: GrantFiled: January 31, 2014Date of Patent: March 22, 2016Assignee: THEAPRIN PHARMACEUTICALS INC.Inventors: Harry G. Brittain, Philip V. Felice
-
Patent number: 9271989Abstract: The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine.Type: GrantFiled: March 10, 2015Date of Patent: March 1, 2016Assignee: CMPD LICENSING, LLCInventors: Jay Richard Ray, II, Charles D. Hodge
-
Patent number: 9140703Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.Type: GrantFiled: October 25, 2010Date of Patent: September 22, 2015Assignee: The Cleveland Clinic FoundationInventors: Stanley L. Hazen, Renliang Zhang
-
Patent number: 9056139Abstract: The invention provides compositions and methods for treating or preventing cancer with an inventive composition. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.Type: GrantFiled: June 28, 2013Date of Patent: June 16, 2015Assignee: KEAN UNIVERSITYInventor: Evros Vassiliou
-
Publication number: 20150139973Abstract: The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue of the eye. The vehicle system is suitable for the prophylaxis and/or treatment of diseases of the front and/or back portion of the eye. Likewise, the present invention relates to an ophthalmological kit, comprising a special ophthalmological composition and also, as separate formulation, an ophthalmological active substance.Type: ApplicationFiled: May 14, 2013Publication date: May 21, 2015Inventors: Ute Steinfeld, Frank Holzer, Hyeck Hee Lee, Markus Mahler
-
Publication number: 20150125525Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: ApplicationFiled: April 29, 2013Publication date: May 7, 2015Applicant: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Goutte, Abdul Waseh Basit, Felipe Jose, Oliveira Varum, Ana Cristina Freire
-
Patent number: 9023369Abstract: The invention relates to freeze-dried molded articles, containing ?50% by wt. of one or more active substances, and ?15% by wt. of one or more scaffold-forming agents, with proteins being excepted, as well as optionally one or more auxiliary substances, in each case based on the total composition of the freeze-dried molded article, whose 1% by wt. solution or suspension in water, at 20° C., has a pH value <7. Furthermore, the invention relates to methods for manufacturing these freeze-dried molded articles, the combination of such freeze-dried molded articles in kit-of-parts arrangements together with aqueous solutions, as well as the use of the freeze-dried molded articles and the kit-of-parts combinations for pharmaceutical and cosmetic application.Type: GrantFiled: April 20, 2010Date of Patent: May 5, 2015Inventors: Ralf Malessa, Claudia Elsinghorst, Fabian Kuhlmann, Uwe Wagner
-
Publication number: 20150118303Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.Type: ApplicationFiled: November 12, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Patent number: 9018193Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.Type: GrantFiled: September 13, 2011Date of Patent: April 28, 2015Assignee: Bev-Rx, Inc.Inventor: Kyle A. Reed
-
Patent number: 8999961Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: GrantFiled: July 19, 2013Date of Patent: April 7, 2015Assignees: Purdue Pharma, L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150080353Abstract: The subject invention relates to compositions and methods useful for the in vivo delivery of substantially water-insoluble drugs, like taxol. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable.Type: ApplicationFiled: November 6, 2014Publication date: March 19, 2015Inventors: Mewa SINGH, Maninder SANDHU
-
Publication number: 20150072961Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: November 14, 2014Publication date: March 12, 2015Inventors: Chongxi YU, Lina XU
-
Publication number: 20150072005Abstract: Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition.Type: ApplicationFiled: September 10, 2013Publication date: March 12, 2015Inventor: Joseph P. Habboushe
-
Publication number: 20150051161Abstract: The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease. In particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes.Type: ApplicationFiled: April 10, 2014Publication date: February 19, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Richard David Semba, Luigi Ferruci, Edward G. Lakatta
-
Publication number: 20140370011Abstract: The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders.Type: ApplicationFiled: September 4, 2014Publication date: December 18, 2014Applicant: DARA BIOSCIENCES, INC.Inventor: Mary Katherine Delmedico
-
Publication number: 20140356348Abstract: Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the absence or a non-detectable level of antibodies specifically binding to alpha2M is associated with a history of RPL and an increased risk of pregnancy loss. Also described are methods for identifying subjects at risk of pregnancy loss, selecting subjects for participation in a clinical study, and methods of decreasing the risk of pregnancy loss in a subject which include detecting the presence or absence of antibodies to one or more of trophoblast-derived ApoB-100, alpha2M, and fibronectin. Also provided are kits that contain ApoB-100, alpha2M, and fibronectin.Type: ApplicationFiled: May 13, 2014Publication date: December 4, 2014Applicant: University of Louisville Research Foundation, Inc.Inventors: Douglas D. Taylor, Cicek Gercel-Taylor
-
Publication number: 20140348818Abstract: Biomarkers of Kawasaki Disease (KD) are provided. In certain aspects, methods are provided for detecting KD biomarkers, such as elevated PDGFC expression. Likewise, methods of treating a subject having a biomarker of KD are described.Type: ApplicationFiled: December 21, 2012Publication date: November 27, 2014Inventors: Virginia M. Pascual, Zhaohui Xu, Octavio Ramilo, Rolando Cimaz
-
Publication number: 20140341988Abstract: Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered.Type: ApplicationFiled: May 15, 2014Publication date: November 20, 2014Applicant: APR APPLIED PHARMA RESEARCH SAInventors: Alberto REINER, Giorgio REINER
-
Publication number: 20140335153Abstract: A method of preparing a thin film, the method comprising: (a) mixing a lipid, emulsifier, and solvent to provide a uniform first mixture; (b) contacting an active ingredient with the uniform first mixture to provide a thickened second mixture; (c) contacting a binder with the thickened second mixture to provide a slurry; and (d) hot extruding, casting, and condensing the slurry to provide the thin film; or cooling, shearing, mixing, casting, and condensing the slurry to provide the thin film.Type: ApplicationFiled: October 31, 2013Publication date: November 13, 2014Applicant: CURE Pharmaceutical CorporationInventors: Eric Allen, Robert Steven Davidson, Jose Bernardo
-
Publication number: 20140329779Abstract: The invention discloses a solid transparent vehicle utilizing DBS in which a topical pharmaceutical active or cosmetic active is solubilized without the use of a monohydric and/or polyhydric alcohol thus providing a non-tacky, clear solid, which prevents segregation and insures uniformity in dosing.Type: ApplicationFiled: January 22, 2013Publication date: November 6, 2014Applicant: PRODUCT AND TECHNOLOGY PARTNERS LLCInventors: Leonard Mackles, William Bess
-
Publication number: 20140328913Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.Type: ApplicationFiled: July 18, 2014Publication date: November 6, 2014Inventors: Roger A. Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollack, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
-
Publication number: 20140322328Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.Type: ApplicationFiled: July 24, 2013Publication date: October 30, 2014Applicant: OtiTopic, Inc.Inventor: Kambiz Yadidi
-
Patent number: 8871246Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.Type: GrantFiled: August 6, 2013Date of Patent: October 28, 2014Inventor: Lawrence Richard Bernstein
-
Patent number: 8865687Abstract: The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.Type: GrantFiled: February 14, 2013Date of Patent: October 21, 2014Assignee: N.V. NutriciaInventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
-
Publication number: 20140274975Abstract: The invention provides methods and compositions for diagnosing prior ischemic stroke or transient ischemic attack (TIA) and approximate the time said stroke occurred, comprising measurement of IgG and IgM antibodies to NR2A and/or NR2B NMDA receptor or fragment thereof in a biological sample, and comparing those measurements to reference population standards and to each other. The invention also includes optionally measuring other biomarkers for autoimmune disease for the reduction in false positives and better risk stratification for future stroke events. The method is particularly useful for identifying individuals that are at risk for future stroke or TIA, and for diagnosing previous history of ischemic stroke or TIA. This measurement and comparison enables determination of the risk of future stroke which is by definition higher in those patients who have suffered a previous stroke.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Health Diagnostic Laboratory, Inc.Inventors: Rebecca E. CAFFREY, Mohmed ASHMAIG